Pan-Echinocandin-Resistant Candida glabrata Bloodstream Infection Complicating COVID-19: A Fatal Case Report

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

(2020) Victor M Corman et al.   Eurosurveillance

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

(2020) Qiurong Ruan et al.   INTENSIVE CARE MEDICINE

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

(2020) Nanshan Chen et al.   LANCET

High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis

(2020) Bing Zhai et al.   NATURE MEDICINE

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

(2020) Lihua Zhu et al.   Cell Metabolism

COVID-19, superinfections and antimicrobial development: What can we expect?

(2020) Cornelius J Clancy et al.   CLINICAL INFECTIOUS DISEASES

Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing

(2020) Timothy M Rawson et al.   CLINICAL INFECTIOUS DISEASES

Clinical features and development of sepsis in patients infected with SARS-CoV-2: a retrospective analysis of 150 cases outside Wuhan, China

(2020) Di Ren et al.   INTENSIVE CARE MEDICINE

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

(2020) Jing Yang et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(2020) Fei Zhou et al.   LANCET

SARS-CoV-2 and viral sepsis: observations and hypotheses

(2020) Hui Li et al.   LANCET

Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure

(2020) Amir Arastehfar et al.   MYCOSES

Different detection capabilities by mycological media for Candida isolates from mono- or dual-species cultures

(2020) Giulia De Angelis et al.   PLoS One

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

(2020) Alfonso J. Rodriguez-Morales et al.   Travel Medicine and Infectious Disease

Invasive fungal diseases during COVID-19: We should be prepared

(2020) J.-P. Gangneux et al.   JOURNAL DE MYCOLOGIE MEDICALE

Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016–2018)

(2020) Amir Arastehfar et al.   MEDICAL MYCOLOGY

COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment

(2020) Amir Arastehfar et al.   Journal of Fungi

Diabetes, infection risk and COVID-19

(2020) Suheda Erener   Molecular Metabolism

The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens

(2020) Amir Arastehfar et al.   Journal of Fungi

Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016

(2019) Michael A Pfaller et al.   Open Forum Infectious Diseases

Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for FKS-Associated Echinocandin Resistance in Candida glabrata Septic Arthritis and Osteomyelitis

(2019) William F. Wright et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Infectious Threats, the Intestinal Barrier, and Its Trojan Horse: Dysbiosis

(2019) Simona Iacob et al.   Frontiers in Microbiology

Echinocandin resistance among Candida isolates at an academic medical centre 2005–15: analysis of trends and outcomes

(2018) Todd P McCarty et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection

(2018) Christoph A. Thaiss et al.   SCIENCE

Spontaneous Mutational Frequency and FKS Mutation Rates Vary by Echinocandin Agent against Candida glabrata

(2018) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Invasive Fungal Infections in the Intensive Care Unit

(2017) Luis Ostrosky-Zeichner et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

The global problem of antifungal resistance: prevalence, mechanisms, and management

(2017) David S Perlin et al.   LANCET INFECTIOUS DISEASES

In vitro exposure to increasing micafungin concentrations easily promotes echinocandin resistance in Candida glabrata isolates

(2016) María Ángeles Bordallo-Cardona et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

(2016) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Abdominal Candidiasis Is a Hidden Reservoir of Echinocandin Resistance

(2014) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Echinocandin resistance

(2014) Maiken C. Arendrup et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Development and Validation of an In-House Database for Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry-Based Yeast Identification Using a Fast Protein Extraction Procedure

(2014) E. De Carolis et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Caspofungin MICs Correlate with Treatment Outcomes among Patients with Candida glabrata Invasive Candidiasis and Prior Echinocandin Exposure

(2013) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid Emergence of Echinocandin Resistance in Candida glabrata Resulting in Clinical and Microbiologic Failure

(2013) James S. Lewis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

(2013) Barbara D. Alexander et al.   CLINICAL INFECTIOUS DISEASES

Candida glabrata: a review of its features and resistance

(2013) C. F. Rodrigues et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Fks1 and Fks2 Are Functionally Redundant but Differentially Regulated in Candida glabrata: Implications for Echinocandin Resistance

(2012) Santosh K. Katiyar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Presence of anFKSMutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata

(2012) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Candida glabrataMutants Demonstrating Paradoxical Reduced Caspofungin Susceptibility but Increased Micafungin Susceptibility

(2011) Kelley R. Healey et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin ResistanceIn Vivo

(2011) Keunsook K. Lee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains

(2010) M. Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3- -D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint

(2009) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY